Introduction
At the second Dialysis Access Symposium (DAS) held in Nagoya, a proposal was made to investigate the differences in vascular access (VA) methods used in different countries. In this article, we describe the status of VA in Japan.
Patients with kidney failure
Statistics for patients with kidney failure are summarized in Table 1 .
Population
The population of Japan peaked in 2010 at 128,057 million and since then has been declining. The proportion of elderly individuals in the population is continuing to increase, with 26.6% of the population aged 65 years or above, 12.8% aged 75 years or above, and 3.9% aged 85 years or above, and those aged 100 years or above at the end of 2015 is 62,000 persons. 1 peritoneal dialysis (PD) was 9322 and has been decreasing in recent years. 2 
Number of kidney transplants
A total of 1648 kidney transplants were performed, of which 1471 were from living donors, 61 were from cadavers, and 116 were from brain-dead donors. There has been no significant change in the number of transplants performed since 2012. 3 The total number of kidney transplants in Japan is very small.
Number of dialysis facilities
There are 4321 dialysis facilities in Japan, with 133,538 bedside consoles available. 2 
Types of VA
The most recent national survey of VA in Japan was carried out in 2008 by the Japanese Society for Dialysis Therapy (JSDT) as the JSDT Renal Data Registry (JRDR). 4 An arteriovenous fistula (AVF) was used in 89.7% of cases, an arteriovenous graft (AVG) in 7.1%, superficialization of the brachial artery in 1.8%, and a permanent catheter in 0.5%.
In 2015, the Japanese Society for Dialysis Access (JSDA) carried out a survey among the institutions with which JSDA members determined the current status of VA and, particularly, changes in the VA environment as a result of the increase in elderly patients. 5 As that survey was carried out by the JSDA, it may be assumed to cover facilities, doctors, and technicians with an interest in VA. We therefore include it for reference purposes, with the caveat that it may not necessarily reflect the circumstances in general hospitals nationwide. As some years had elapsed between the two surveys, its results cannot therefore be compared directly with those of the JSDT survey.
In the JSDA survey, AVF was used in 84.1% of cases, AVG in 9.9%, superficialization of the brachial artery in 1.8%, and a permanent catheter in 0.5%.
Devices, healthcare system, insurance reimbursements, and related matters

Medical service fees
Details of medical service fees and insurance reimbursements are set out in Table 2 .
In Japan, the fees for medical services provided under the national health insurance system are specified by the government. This means that patients are basically able to access all medical treatments by paying the prescribed copayment. Dialysis patients are also eligible for certain exemptions, and under this system, they are able to receive medical care at very low out-of-pocket cost. In Japan, the same fees are charged regardless of which doctor sees a patient and whichever institution they attend.
The cost is US$1600 for an AVF, US$2680 for an AVG, and US$442 for superficialization of the brachial artery. For many years, permanent catheter insertion was not included in the medical fee schedule, but today, its cost is specified as US$221, a low amount in consideration of the complexity of this procedure. As external shunts are practically never performed in Japan, this procedure is not covered in the medical fee schedule. Percutaneous transluminal angioplasty (PTA) was long treated as a low-cost procedure, with a fee of US$280. When the medical fee schedule was revised, a new category was created including PTA/thrombectomy at a cost of US$1600, the same as for AVF. The costs of any diagnostic imaging and tests involved in this procedure cannot be priced into this item, and the schedule stipulates that it can only be invoiced once in 3 months.
Insurance reimbursement
The reimbursement costs for medical devices are set in the same way as those of medical procedures, and there are strict restrictions on the devices that can be used (Figure 2 ). PTA catheters are divided into standard, special, cutting, and non-slipping types. The standard type is defined as having a catheter shaft with an external diameter exceeding 4 Fr and not requiring the assistance of a guiding catheter or other device to reach the target lesion site and is differentiated from special catheters. In practice, the reimbursement costs of all types of catheters have been reduced in each biannual revision to the medical fee schedule. Vascular grafts are categorized into standard, selfsealing, and heparin-bonded types. Their reimbursement cost is set per centimeter, and insurance reimbursements are invoiced according to the length of graft used.
The use of endovascular stents in access vessels is not covered by health insurance, and in practice, iliac artery stents are used at the discretion of the doctor. Balloon expandable and self-expandable iliac artery stents are available, but stent grafts may not be used.
Patency rate of VA
Although a few studies have reported patency rates in individual facilities, as no large-scale Japanese study has been conducted, we are unfortunately unable to provide any data. The 2011 edition of the JSDT Guidelines for Vascular Access Construction and Repair for Chronic Hemodialysis states 6 that "The targets for patency rates after AVG should be 60% for primary patency and 80% for assisted patency after 1 year, 60% after 3 years, and 40% after 5 years."
Type of doctor providing VA treatment
As no large-scale study has been performed, we report the results of a survey of VA management carried out by the JSDA in member institutions. 5 This survey covered doctors involved in the creation or repair of VA in 2015 in JSDA-member institutions, and the sample size (approximately 16,000 individuals) was around 5% of that of the JSDT national survey.
As mentioned above, the results were obtained from JSDA-member institutions with an interest in VA, and it must be understood that they may not necessarily reflect the actual numbers on a national level.
In 92% of cases, AVF creation was carried out by doctors involved in dialysis treatment. Of these, 33% were nephrologists, 25% urologists, 20% general surgeons, and 12% vascular surgeons. The figures for repair were similar. AVG was performed by doctors involved in dialysis in 96% of cases, 27% of whom were nephrologists, a slightly lower proportion compared with AVF creation, and 25% were urologists. PTA was performed by nephrologists in 39% of cases, followed by general surgeons and urologists at 20% of cases each. The procedure most often performed by doctors not normally involved in dialysis was AVG repair in 10% of cases.
Characteristics and issues of patients with renal failure in Japan
Old age
The increasing age of patients with renal failure is a major issue in Japan (Figure 1 ). In 2015, the mean age of patients starting dialysis was 69.2 years, and the mean age of patients at the end of the year was 67.7 years (Figure 1) . 2 In 2005, the equivalent figures were 66.2 and 63.9 years, with the mean age of patients rising by 1 year approximately every 3 years. By the Tokyo Olympics (in 2020), both these mean ages are projected to exceed 70 years. In 2015, patients aged 65 years or above accounted for 65.1% of all dialysis patients, a much higher proportion than the 26.8% of the population as a whole aged 65 years or above. 1 This shows that elderly people are the main recipients of medical care for renal failure. Naturally, agingassociated arteriosclerosis in the limbs and diminished cardiac function are likely, as is the treatment-induced fragility of superficial vessels, and it is envisaged that these will cause problems for VA creation and management in future.
Underlying conditions
Until 1998, the most common underlying condition requiring the introduction of dialysis was CGN; in 1998, this was surpassed by DN, which rose to account for 43.7% of patients, compared with only 16.9% at the end of 1995 (Figure 2) . The proportion of patients with CGN has continued to decrease and has now dropped to a rate close to that of nephrosclerosis (NS), which is currently in third place at 14.2% and is expected to overtake CGN in the near future. Looking at the year-end proportions of patients, CGN was in first place until 2011, when it was overtaken by DN. In 2015, DN was in the lead, accounting for 38.4% of patients. The rising number of patients with DN and NS, who may also have a higher incidence of cardiovascular problems, may thus entail increasing problems for VA creation and management in future, in the same way as those posed by increasing patient age (Figure 3 ). 4 Issues in VA creation and management in Japan
VA creation
As described above, when patients in whom damage to arteries, reduced cardiac function, and fragile superficial vessels are matters of concern, such as elderly people and patients with conditions such as diabetes or hypertension, develop renal failure, they must start renal replacement therapy. Few older people are eligible for a kidney transplant, and as very few institutions in Japan are capable of performing kidney transplantation even for younger patients, dialysis is the main method of treatment used. As HD is performed in 97% of cases and PD in only 2.8%, the overwhelming majority of patients are thus necessarily started on HD. There are a number of reasons that PD has yet to be widely adopted in Japan, but these will not be addressed in this article.
The conditions are thus unfavorable for VA creation, but as is well known, the AVF rate is higher than that in other countries and the rate of catheter use is lower. 7 Although the decision to convert to AVG is not taken lightly, as mentioned earlier the number of patients with fragile vessels has been rising in recent years and this procedure is therefore also increasingly being used in Japan. Superficialization of the brachial artery is also actively being used for patients with reduced cardiac function, and this surgical procedure is covered by health insurance.
VA management
PTA is the main method used for performing AVF, AVG, and other shunt-type VA repair procedures in Japan. Plain old balloon angioplasty (including use of ultrahigh-pressure balloons) is widely used for dilating stenotic regions, but peripheral cutting balloons and nonslipping elements may also be used. Unfortunately, although drug-coated balloons (DCBs) have been approved for use in cardiologic procedures, their use in shunt procedures is not covered by medical insurance. A clinical trial of paclitaxel-coated DCBs is currently underway in Japan, and it is hoped that these will become available for use in the future.
Thrombotic obliteration may be treated by either PTA or surgical division, depending on the preference of the operator. Two types of devices are approved for use in PTA: thrombo-aspiration catheters and pharmaco-thrombolysis devices. Hydrodynamic thrombectomy devices were formerly also used, but for various reasons these are unfortunately no longer available. The Trerotola percutaneous thrombolytic device and other devices for thrombolysis and aspiration are also no longer in use.
If PTA is difficult to use for shunt-type access, surgical division is performed. Reconstruction is carried out from as distal a point as possible, and if the radial artery cannot be used, then reconstruction may be carried out in the brachial or ulnar artery. Although the decision to convert to AVG is not taken lightly, as mentioned earlier, the number of patients with fragile vessels has been rising in recent years, and this procedure is therefore also increasingly being used. Superficialization of the brachial artery or the use of a permanent catheter is ultimately required in a not insignificant number of patients. 4 Among patients who have been undergoing dialysis for 10 years, 90% can be managed by AVF, but this rate decreases to 81% of those who have been undergoing dialysis for 25 years, and in this population, the proportion managed by an AVG rises to 12.5% and by a permanent catheter to 1.0%.
Discussion
In brief, an increasing number of dialysis patients in Japan are elderly and have DN or NS. The rate of increase in the proportion of older patients far outstrips that of the general population, with 65.1% of dialysis patients now aged 65 years or above. The increasing number of patients with DN and NS, who may also have multiple other conditions, is undoubtedly a major risk for increased medical costs in Japan in future.
The yearly increase in the number of dialysis patients is also decreasing. Although this is a favorable trend, it does entail its own problems. The positive aspect is that the rate of increase in the number of patients starting dialysis is declining owing to a range of efforts. However, the negative aspect is that crude death rate 2 was 9.6% in 2015, a slight increase over the 9.0% rate in 1963. If this situation continues, within a few years, the number of people dying will outstrip the number starting dialysis, and the number of dialysis patients will start to decrease. Moreover, the net increase in the number of patients is only around one person per institution, and it can easily be envisaged that some institutions may run into business difficulties in the future. One major factor in this situation is the increasing number of patients with DN and NS, whose prognosis may be poor, but the cause of death that has exhibited the greatest increase is actually infection; the increased use of VA techniques involving foreign bodies such as AVG and permanent catheterization may be one reason for this rise. 8, 9 Despite these unfavorable circumstances, the survival prognosis for dialysis patients in Japan is good, as has been shown by the Dialysis Outcomes and Practice Patterns Study (DOPPS). 10 Although there may be several reasons for this, we consider that the existence of "dialysists" is a major factor. As shown in Table 3 , doctors in a range of fields (including nephrologists, surgeons, and urologists) are engaged in the creation and management of VA in Japan. The establishment of this system means that VA can be created to provide the appropriate perfusion required for dialysis, treatment can be provided before blood flow becomes insufficient for inadequate dialysis, and VA providing excessive blood flow that would increase the strain on the heart is not overlooked, enabling steps to be taken to control perfusion. Efforts to avoid the routine use of AVF and permanent catheterization, which entail the insertion of foreign material into the body, may also be contributing to the improvement in prognosis. Nevertheless, long-term HD will inevitably necessitate the increased use of such foreign materials, 4 raising concerns that survival may worsen in the future.
Conclusion
We hope that the plan proposed at the DAS to compare the situation in Japan described in this article with the circumstances in other countries will enable the identification of differences in the environments in which VA is performed worldwide, leading to improvements in the management of VA in future.
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